Aggregated from the cited literature below. We summarize sources — we don't author claims.
Sermorelin is discussed in the provided sources as a growth hormone secretagogue/growth hormone releasing hormone (GHRH) synthetic analog that is considered among compounds affecting GH/IGF-1 signaling pathways, and it also appears in research focused on doping detection and analytical stability/detection methods. (PMIDs: 41490200, 41966639, 34665524, 32257855, 37806509, 36787346)
Mechanism (as reported)
Research described sermorelin as part of the growth hormone secretagogues, reported to be GH and IGF-1 stimulators, and discussed in the context of activating IGF-1 signaling and pathways related to tissue repair/satellite cell involvement. (PMIDs: 41490200, 41966639, 32257855, 34665524)
Key findings (each cites a source)
A review on therapeutic peptides in orthopaedics lists sermorelin among growth hormone secretagogues that are reported to activate IGF-1 signaling and satellite cell repair, and it notes that there is a lack of clinical trials despite promising preclinical studies. [PMID 41490200]
A narrative review on peptide therapies for musculoskeletal injuries in sports medicine includes sermorelin among prominent approved/unapproved peptides marketed direct to patients and states that rigorous human safety data are scarce for many unapproved peptides. [PMID 41966639]
Research investigated in vitro metabolism and detection of GHRH synthetic analogs including sermorelin in fortified urine, identifying multiple metabolites and using them to develop a sensitive LC-MS/MS method for detection to support evidence of GHRH administration. [PMID 34665524]
A review addressing growth hormone secretagogues in body composition discussed sermorelin as a GH and IGF-1 stimulator and described that data on clinical effects remain limited, creating opportunities for future investigation. [PMID 32257855]
Analytical work on in-house standards derived from doping peptides evaluated enzymatic and serum stability of sermorelin fragments (e.g., Sermorelin (1-11), (13-20), (22-29)) and reported that selected sermorelin fragment(s) (including Sermorelin (22-29)) can be considered stable to enzyme and blood treatment and used as internal standards in quantification workflows. [PMID 37688464]
A validated urine method for detecting GHRH analogs reported inclusion of sermorelin forms (including sermorelin (GRF 1-29) and sermorelin (3-29)-NH2) using a triple quadrupole UHPLC/MS-MS approach with SPE, describing sensitivity and performance characteristics aligned with anti-doping laboratory screening requirements. [PMID 37806509]
A capillary electrophoresis study proposed analysis of GHRH analogs including sermorelin (and CJC-1293) and reported chiral separation of enantiomeric/basic analogs and application to urine after desalting, with method-sensitivity results reported as limits of detection. [PMID 36787346]
Vendor test rankings (7)
Vendors ranked by their independent third-party test grade for Sermorelin, attributed to Finnrick. The grade is their verdict, not ours.
Real third-party HPLC results aggregated from Peptigrity, each attributed to the lab that ran it — average purity 99.4% across 217 tests. Not our verdict.
Papadia A, Schally AV, Halmos G, Varga JL, Seitz S, Buchholz S · Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2011 · PMID 22009378
Pandya N, DeMott-Friberg R, Bowers CY, Barkan AL, Jaffe CA · The Journal of clinical endocrinology and metabolism · 1998 · PMID 9543138
FAQ
What is Sermorelin?
Sermorelin (Sermorelina, 86168-78-7, Sermoreline) is classified under ghrh analogs, which has been withdrawn from approved use. Research goals associated with it include gh axis support.
Is Sermorelin FDA-approved?
Sermorelin has been withdrawn from approved use.
What does the research on Sermorelin say?
peptideone aggregates 14 references from PubMed for Sermorelin. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.